irinotecan has been researched along with Pharyngeal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higuchi, S; Ieiri, I; Kawamoto, K; Kitano, H; Moriki, K; Otsubo, K; Sasaki, T; Takane, H | 1 |
| Eguchi, K; Karato, A; Kojima, A; Kunikane, H; Ohe, Y; Ohmatsu, H; Okamoto, H; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
1 trial(s) available for irinotecan and Pharyngeal Neoplasms
| Article | Year |
|---|---|
Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Diarrhea; Drug Evaluation; Esophageal Neoplasms; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Middle Aged; Pharyngeal Neoplasms | 1992 |
1 other study(ies) available for irinotecan and Pharyngeal Neoplasms
| Article | Year |
|---|---|
Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pharmacogenetics; Pharyngeal Neoplasms | 2009 |